We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On June 28, the CDE official website showed that Novartis' siRNA long-acting lipid-lowering drug Inclisiran submitted a clinical application in China and has been accepted and accepted.